EPS for Biomerica, Inc. (BMRA) Expected At $-0.03

September 17, 2017 - By Nellie Frank

 EPS for Biomerica, Inc. (BMRA) Expected At $ 0.03

Analysts await Biomerica, Inc. (NASDAQ:BMRA) to report earnings on October, 16. They expect $-0.03 EPS, down 200.00 % or $0.02 from last year’s $-0.01 per share. After $-0.04 actual EPS reported by Biomerica, Inc. for the previous quarter, Wall Street now forecasts -25.00 % EPS growth. The stock decreased 1.07% or $0.03 on September 15, reaching $2.78. About 13,027 shares traded or 26.93% up from the average. Biomerica, Inc. (NASDAQ:BMRA) has risen 66.46% since September 17, 2016 and is uptrending. It has outperformed by 49.76% the S&P500.

Biomerica, Inc. is a biomedical company, which develops, makes and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company has market cap of $23.66 million. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care . It currently has negative earnings. The Firm operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: Quotes.Wsj.com which released: “Biomerica Inc.” on February 27, 2011, also Globenewswire.com with their article: “Biomerica Announces Point of Care Product Distribution Agreement with a …” published on August 16, 2017, Globenewswire.com published: “Biomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test” on September 12, 2017. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: Marketwatch.com and their article: “2.78” published on April 19, 2011 as well as Globenewswire.com‘s news article titled: “Biomerica Announces Fiscal Year End 2017 Financial Results; Sales Up 12.7% for …” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: